Welcome to our dedicated page for Evaxion AS news (Ticker: EVAX), a resource for investors and traders seeking the latest updates and insights on Evaxion AS stock.
Evaxion A/S reports developments as a clinical-stage TechBio company using its proprietary AI-Immunology™ platform to design vaccine candidates for cancer and infectious diseases. Company news commonly covers EVX-01, its personalized peptide-based cancer vaccine for advanced solid cancers, including data from a phase 2 advanced melanoma trial and measures of neoantigen target selection and immune response.
Updates also address platform applications beyond melanoma, including glioblastoma vaccine design, prophylactic infectious disease concepts such as polio and cytomegalovirus programs, collaborations, business development activity, quarterly financial results, annual general meeting outcomes, board matters, and management-role changes.
Evaxion Biotech A/S (NASDAQ: EVAX) has completed its follow-on public offering of 3,942,856 American Depositary Shares (ADSs) at a price of $7.00 per ADS. The offering included the full exercise of the underwriters’ option to purchase an additional 514,285 ADSs, generating approximately $27.6 million in gross proceeds before deductions. The ADSs are traded on the Nasdaq Capital Market. Oppenheimer & Co. Inc. served as the sole book-running manager for this offering, with additional support from Ladenburg Thalmann & Co. Inc. and Lake Street Capital Markets, LLC.
Evaxion Biotech reported Q3 2021 financial results, highlighting a follow-on public offering (FPO) of 3.9 million ADSs expected to raise $27.6 million. Key developments include positive Phase 1/2a trial results for EVX-01, showing a 67% patient benefit rate in metastatic melanoma, and EVX-02 demonstrating T-cell activation. Cash reserves were $11.9 million, bolstered by the FPO. The company's net loss was $5.3 million, slightly higher than the previous year. Upcoming milestones include Phase 2b trials for EVX-01 and EVX-02 in early 2022.
Evaxion Biotech A/S (NASDAQ: EVAX) has announced the pricing of a follow-on public offering of 3,428,571 American Depositary Shares (ADSs) at $7.00 each, aiming to raise approximately $24 million before fees. The offering, expected to close on November 9, 2021, includes an option for underwriters to purchase an additional 514,285 ADSs. Oppenheimer & Co. Inc. serves as the book-running manager. Evaxion is focused on developing AI-driven immunotherapies for various diseases, with several candidates in clinical development.
Evaxion Biotech A/S (Nasdaq: EVAX) announced the filing of a Registration Statement with the SEC for a proposed follow-on public offering of American Depositary Shares (ADSs). The offering will include an option for underwriters to purchase an additional 15% of the ADSs. The specific details regarding the number and price of shares are yet to be determined. Oppenheimer & Co. Inc. and Raymond James & Associates, Inc. are managing the offering, which is subject to market conditions and the Registration Statement's effectiveness.
Evaxion Biotech A/S (NASDAQ: EVAX) has announced a collaboration with Merck & Co. to conduct a Phase 2b clinical trial for its cancer immunotherapy EVX-01 in combination with KEYTRUDA® (pembrolizumab). The trial will focus on patients with metastatic melanoma (stage III and IV) and aims to begin in Q4 2021. Evaxion will lead the study, while Merck provides KEYTRUDA®. Previous promising results from Phase 1/2a trials suggest EVX-01 may enhance melanoma treatment efficacy.
Summary not available.
Evaxion Biotech A/S (NASDAQ: EVAX) announced that Dr. Emma Christine Jappe will present at the Immuno UK conference on October 13-14, 2021. The presentation titled "AI-Based Methods to Decode the Immune System and Improve Immunotherapy Design in Cancer" will showcase Evaxion's AI-immunology core technology and its proprietary PIONEER platform. This platform focuses on identifying patient-specific neoepitopes for cancer immunotherapy. Additionally, Dr. Jappe will discuss advancements in neoepitope binding and thermal stability, with findings published in Nature Communications.
Evaxion Biotech A/S (NASDAQ: EVAX) announced the promotion of Birgitte Rønø, Ph.D., to the role of Chief Scientific Officer (CSO). Dr. Rønø, previously Senior Director of Immuno-Oncology, has significantly contributed to Evaxion's oncology pipeline. This newly-created position enhances the leadership team at a critical time, as two lead products are set to advance into Phase 2b trials by mid-2022. With over 15 years of experience in biopharmaceutical drug discovery, Dr. Rønø aims to expand Evaxion's innovative drug development efforts.
Evaxion Biotech reported encouraging clinical progress in Q2 2021, with strong data from its EVX-01 and EVX-02 programs leading to planned Phase 2b trials. EVX-01 demonstrated a 67% patient benefit rate when combined with anti-PD-1 treatment for metastatic melanoma, outperforming historical rates of 40%. The company holds $18.8 million in cash, sufficient to fund its key programs into 2022. Additionally, Evaxion's RAVEN AI platform shows promise in vaccine design targeting coronavirus variants.
Evaxion Biotech (NASDAQ: EVAX) reported promising results from its Phase 1/2a trial of EVX-01 in metastatic melanoma. The therapy, combined with anti-PD1 treatment, resulted in a 67% Objective Response Rate (ORR), with 22% achieving complete responses and 44% partial responses. The study demonstrated a favorable safety profile, noting only Grade 1 and 2 adverse events. The company plans to advance EVX-01 into a Phase 2 trial by December 2021 and has generated data from the EVX-02 trial, showing T-cell activation. Overall, these findings support the innovative AI-Immunology platform, PIONEER.